Engineered Immunotherapy Improves Treatment for Brain Cancer
Researchers have found that CAR-T cell therapy, a form of immunotherapy, shows promise in treating glioblastoma in preclinical mouse models. This approach engineers a patient's own immune cells to identify and destroy aggressive brain cancer cells.
Why it matters
Glioblastoma is notoriously difficult to treat, and this research offers a potential breakthrough for improving survival rates in aggressive brain cancers.
Brain cancer is a highly aggressive form of uncontrolled cell growth. What makes brain cancer difficult to treat is its very location. It is difficult to resection the entire tumor and many drugs fail to pass the blood brain barrier (BBB) - the protective barrier surrounding the brain. The rich nutrient environment around the brain also helps fuel the malignancy and progress. Some symptoms of brain cancer include frequent and severe headaches, nausea/vomiting, changes in vision, difficulty with coordination, seizures, confusion, poor memory, change in mood, and personality. Brain tumors are detected by neurological exams such as vision, hearing, balance, and reflex testing. Physicians also use imaging techniques and take biopsy samples to confirm diagnose. Other than surgery, patients are treated with chemotherapy and/or radiation therapy. Scientists and physicians are working to enhance current treatment strategies and improve patient survival.
The article provides a scientific summary of medical research without ideological bias.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in